Viridian Therapeutics Prices Upsized $350M Concurrent Offering of Convertible Notes and Common Stock

summarizeSummary

Viridian Therapeutics announced the pricing of its upsized concurrent public offerings, raising $350.0 million in gross proceeds through convertible senior notes and common stock, providing substantial capital for debt repayment and pipeline advancement.

check_boxKey Events

• Upsized Concurrent Offerings Priced

  Viridian Therapeutics priced its upsized concurrent public offerings, raising an aggregate gross proceeds of $350.0 million. This finalizes the terms of the offering initiated on May 5, 2026, and represents a significant increase from the initially targeted $250 million.

• Convertible Senior Notes Details

  The offering includes $225.0 million aggregate principal amount of 1.75% convertible senior notes due 2032. The initial conversion price is approximately $24.65 per share, representing a 45.0% premium over the common stock offering price.

• Common Stock Offering Details

  The equity component consists of 7,352,942 shares of common stock offered at a public offering price of $17.00 per share.

• Net Proceeds and Use of Funds

  The estimated aggregate net proceeds are approximately $334.7 million. These funds will be used to repay outstanding debt, fund market expansion studies for the thyroid eye disease (TED) franchise, advance earlier pipeline research and development, and for general corporate purposes.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of the concurrent public offerings previously announced on May 5th and 6th, significantly upsizing the total gross proceeds to $350.0 million from an initial target of $250 million. The successful completion of this substantial capital raise, representing approximately 19.37% of the company's market capitalization, provides Viridian Therapeutics with an estimated $334.7 million in net proceeds. This capital is critical for the company, especially following its Q1 2026 report which indicated an increased net loss and cash burn. The funds will be used to repay outstanding debt, support market expansion studies for its thyroid eye disease (TED) franchise, and advance its R&D pipeline, thereby extending its financial runway and supporting strategic growth initiatives. The convertible notes are priced with a 45% conversion premium, indicating investor confidence in future stock appreciation, despite the immediate dilution from the equity component.